Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,592.64
(
0.55%
)
US TECH 100
23,568.00
(
0.89%
)
Dow Jones
46,412.84
(
0.63%
)
Brent Oil
97.60
(
1.14%
)
Bitcoin
70,865.01
(
0.49%
)
News Focus
News Focus
Post# of 257284
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

marthambles

Send PM Follow Ignore
Followers 9
Posts 1369
Boards Moderated 0
Alias Born 04/26/2004

marthambles

Re: MotionMan post# 100506

Tuesday, 08/03/2010 10:38:56 AM

Tuesday, August 03, 2010 10:38:56 AM

Post# of 257284
MotionMan

The appropriate risk to reward ratio has not yet been applied.



Deutche Bank posited an $18 valuation for MNTA in the event of a Teva approval. MNTA is trading at around $22, representing a 22% premium over what I would consider the probable worst case scenario. So, you believe the DB valuation is clearly incorrect, and/or the market is excessively discounting the Teva risk. Which is it, and by how much?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today